No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

byKathleen Lau

March 5, 2021

in StudyGraphics

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

March 2, 2026

AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026

Many new pediatric asthma cases attributable to obesity

Food security status lower effectiveness of lifestyle-based weight loss approaches

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind March 8, 2021

Relationships between depression and anxiety symptoms and adipocyte-derived proteins in postmenopausal women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports